Form 4: Maze Therapeutics Exec Sells $1.8M in Stock

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options and sold 45,000 shares for approximately $1.8 million under a pre-arranged trading plan.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., executed transactions on December 29, 2025.
• Exercised options to acquire 45,000 shares of common stock at an exercise price of $10.42 per share.
• Immediately sold all 45,000 shares in two separate transactions.
• The first sale involved 27,800 shares at a weighted average price of $40.339 per share, with prices ranging from $39.71 to $40.705.
• The second sale involved 17,200 shares at a weighted average price of $40.9262 per share, with prices ranging from $40.73 to $41.51.
• The total proceeds from these sales amounted to approximately $1,829,900.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Following these transactions, Bernstein beneficially owns 342,407 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a routine insider transaction involving the exercise of vested options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates concerns about opportunistic trading. The executive realized a substantial gain.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than an immediate reaction to new information.
• The executive realized a significant gain by exercising options at $10.42 and selling shares at an average price over $40.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake.
• The sale represents a substantial portion of the shares acquired through option exercise.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider's past transactions.

Management Comments

• The filing includes a standard undertaking by the reporting person to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

Insider transactions, particularly sales, are common in the biotechnology and pharmaceutical sectors, especially when executives exercise vested options for liquidity or portfolio diversification. The use of a Rule 10b5-1 plan is a standard practice to mitigate concerns about trading on material non-public information.

Comparison to Industry Standards

• This type of insider transaction (exercise and sell-to-cover or for liquidity) is a routine event for executives in publicly traded companies, particularly in high-growth sectors like biotech where equity compensation is prevalent. There are no specific comparable companies or projects mentioned in this filing to assess against.

Stakeholder Impact

• Shareholders: May observe a slight increase in the public float due to the sale, and potentially interpret the insider sale as a signal, though mitigated by the 10b5-1 plan.
• Employees: No direct impact mentioned.

Next Steps

• The filing does not mention any specific future actions or milestones for the company, as it focuses on a past insider transaction.

Key Dates

Recommendation

The filing details a routine insider transaction where an executive exercised vested options and sold shares under a pre-arranged 10b5-1 plan. This type of transaction is common for liquidity and portfolio diversification and does not inherently signal a change in the company's fundamental outlook. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Sale, Option Exercise, Harold Bernstein, 10b5-1 Plan, Biotechnology, Pharmaceuticals